Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma. This is according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Before the results of this study, we knew that cobimetinib plus vemurafenib could be safely delivered together with highly promising rates of tumour shrinkage; ...Tuesday, 30 September 2014
New Data on Combination Therapies for Melanoma
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma. This is according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Before the results of this study, we knew that cobimetinib plus vemurafenib could be safely delivered together with highly promising rates of tumour shrinkage; ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment